Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
89.65
+2.32 (2.66%)
At close: Dec 5, 2025, 4:00 PM EST
89.00
-0.65 (-0.73%)
After-hours: Dec 5, 2025, 6:37 PM EST
Protagonist Therapeutics Employees
Protagonist Therapeutics had 126 employees as of December 31, 2024. The number of employees increased by 14 or 12.50% compared to the previous year.
Employees
126
Change (1Y)
14
Growth (1Y)
12.50%
Revenue / Employee
$1,660,452
Profits / Employee
$364,357
Market Cap
5.60B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PTGX News
- 4 hours ago - Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera - Business Wire
- 4 weeks ago - Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Accesswire
- 4 weeks ago - Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting - Accesswire
- 7 weeks ago - Johnson & Johnson To Acquire Protagonist? It'd Be A Good Deal To Make - Seeking Alpha
- 2 months ago - Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today - The Motley Fool
- 2 months ago - Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report - Benzinga
- 2 months ago - Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports - Reuters
- 2 months ago - Johnson & Johnson in Talks to Buy Protagonist Therapeutics - WSJ